Pretomanid
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pretomanid |
| DrugBank ID | DB05154 |
| Brand Names (EU) | Dovprela (previously Pretomanid FGK) |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.69% |
Approved Indication (EMA)
Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | candidiasis | 99.69% | DL |
| 2 | leprosy | 99.27% | DL |
| 3 | coronary artery disease | 99.25% | DL |
| 4 | myocardial ischemia | 99.17% | DL |
| 5 | anomalous left coronary artery from the pulmonary artery | 99.08% | DL |
| 6 | HIV infectious disease | 98.85% | DL |
| 7 | oral candidiasis | 98.72% | DL |
| 8 | Bacteroidaceae infectious disease | 98.67% | DL |
| 9 | thrombocytopenia | 98.65% | DL |
| 10 | fascioliasis | 98.63% | DL |
| 11 | acne (disease) | 98.63% | DL |
| 12 | feline acquired immunodeficiency syndrome | 98.49% | DL |
| 13 | simian immunodeficiency virus infection | 98.49% | DL |
| 14 | marcothrombocytopenia with mitral valve insufficiency | 98.48% | DL |
| 15 | hereditary thrombocytopenia with normal platelets | 98.48% | DL |
| 16 | opisthorchiasis | 98.42% | DL |
| 17 | anaerobic bacteria infectious disease | 98.40% | DL |
| 18 | multiple endocrine neoplasia | 98.39% | DL |
| 19 | transient neonatal thrombocytopenia | 98.38% | DL |
| 20 | breast fibrocystic disease | 98.38% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.